Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,289)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01239875 | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | completed | Early Phase 1 | 16 | Mayo ClinicOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03436342 | Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00013533 | Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | completed | Early Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells. | unknown | Early Phase 1 | 9 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04186052 | Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04184414 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04182581 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 18 | Xijing HospitalOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04169932 | The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT04156269 | BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04028440 | γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | unknown | Early Phase 1 | 6 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT03910842 | Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy | unknown | Early Phase 1 | 12 | Timmune Biotech Inc.INDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT01594242 | Autophagy Induction After Bortezomib for Myeloma | completed | Early Phase 1 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01286675 | Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT | completed | Early Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 1, 2019 | clinicaltrials |
| NCT02846935 | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies | completed | Early Phase 1 | 7 | Yogen SaunthararajahOTHER | 1 | Jan 7, 2019 | clinicaltrials |
| NCT01719250 | Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Early Phase 1 | 7 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01861340 | Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT03661554 | BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma(BCMA CAR-T) | unknown | Early Phase 1 | 15 | The Pregene (ShenZhen) Biotechnology Company, Ltd.INDUSTRY | 1 | Sep 10, 2018 | clinicaltrials |
| NCT02971410 | Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Early Phase 1 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT03559764 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Early Phase 1 | 20 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jun 18, 2018 | clinicaltrials |
| NCT03235869 | Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma | withdrawn | Early Phase 1 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT01878708 | A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma | terminated | Early Phase 1 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT02447055 | Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma | withdrawn | Early Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Jul 12, 2016 | clinicaltrials |
| NCT02080416 | Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors | terminated | Early Phase 1 | 1 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 10, 2016 | clinicaltrials |
| NCT02109861 | Microdose Study of Melphalan, Bortezomib and Dexamethasone(Phase-0-MM) | unknown | Early Phase 1 | 6 | Henrik GregersenOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT01959477 | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant | completed | Early Phase 1 | 33 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT02117115 | Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation(GVHD) | completed | Early Phase 1 | 21 | Washington University School of MedicineOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT01537861 | Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma | terminated | Early Phase 1 | 7 | Washington University School of MedicineOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT01396200 | Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine | completed | Early Phase 1 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 26, 2013 | clinicaltrials |
| NCT00017381 | Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | completed | Early Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00704691 | Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas | terminated | Early Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Apr 20, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jan 14, 2020source: clinicaltrials